Project Grant K99HL168075
Award Date
8/15/24
Completion Date
7/31/26
Dollars Obligated
$107K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The federal Project Grant award "USING DEFECTIVE LIPOYLATION AS A WINDOW INTO CARDIAC FUEL CONSUMPTION AND FAILURE" is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $154,568 award, spanning Dec 2024 to Aug 2027, supports research to characterize the cardiac metabolic and functional consequences of lipoyl deficiency at the University of Texas Southwestern Medical Center. The central hypothesis is...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $125,568 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Stanford University. The grant supports research to explore the molecular mechanisms governing the import and regulation of NAD+ within the mitochondrial matrix. This work aims to elucidate how mitochondria maintain adequate NAD+ levels and how this process may become dysregulated in heart failure, a major global health issue. The...
The federal Project Grant award of $673,642 from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research aims to investigate the role of lysosomes in contributing to arrhythmic risk and sudden cardiac death in ischemic heart failure. The primary objectives are to: 1) Determine whether a lysosomal-sarcoplasmic reticulum (SR) microdomain exists in ischemic heart failure; 2) Evaluate whether TRPML1-mediated lysosomal Ca2+ release can trigger SR...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $663,578 to the University of Washington to conduct research on inflammatory and genetic cardiomyopathies. The key objectives are to: 1) help clinicians determine when to order genetic testing and positron emission tomography (PET) scans, 2) develop minimally invasive diagnostic tests to identify the mechanism behind "idiopathic...
The federal Project Grant award of $620,371, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to determine the voltage-sensing domain (VSD) dynamics of cardiac ion channels from the CNBD family, which play a pivotal role in regulating the electrical properties of the heart. The overarching objective is to leverage advanced biophysical techniques, including patch-clamp fluorometry, transition...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $259,464 to The Leland Stanford Junior University to conduct research on "Mitochondrial Therapy in Conjunction with Guideline Directed Medical Therapy in Cardiomyopathy". The primary objectives are to: 1) Determine the mechanism of the protective effects of mitochondria-rich extracellular vesicles (M-EVs) in combination with guideline-directed...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $762,867 to The Johns Hopkins University to conduct research on the role of the protein cofilin-1 in maintaining mitochondrial function and airway epithelial health. The research aims to 1) determine how the loss of cofilin-1 impacts mitochondrial dynamics, 2) assess the effects of cofilin-1 loss on mitophagy and mitochondrial...